Literature DB >> 30244855

Response to Osimertinib in an EGFR Exon 20 Insertion-Positive Lung Adenocarcinoma.

Zofia Piotrowska1, Florian J Fintelmann2, Lecia V Sequist3, Balkrishna Jahagirdar4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30244855     DOI： 10.1016/j.jtho.2018.05.017

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  16 in total

1.  Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations.

Authors:  Ling Lin; Xiaomai Wu; Shuangquan Yan; Yefei Zhu; Zhengqing Yan; Dongqing Lv; Hongfei Ge
Journal:  Onco Targets Ther       Date:  2020-09-30       Impact factor: 4.147

2.  Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial.

Authors:  Gregory J Riely; Joel W Neal; D Ross Camidge; Alexander I Spira; Zofia Piotrowska; Daniel B Costa; Anne S Tsao; Jyoti D Patel; Shirish M Gadgeel; Lyudmila Bazhenova; Viola W Zhu; Howard L West; Tarek Mekhail; Ryan D Gentzler; Danny Nguyen; Sylvie Vincent; Steven Zhang; Jianchang Lin; Veronica Bunn; Shu Jin; Shuanglian Li; Pasi A Jänne
Journal:  Cancer Discov       Date:  2021-02-25       Impact factor: 39.397

3.  EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer.

Authors:  Wenfeng Fang; Yihua Huang; Shaodong Hong; Zhonghan Zhang; Minghui Wang; Jiadi Gan; Wenjing Wang; Honglin Guo; Kai Wang; Li Zhang
Journal:  BMC Cancer       Date:  2019-06-17       Impact factor: 4.430

4.  Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma.

Authors:  Chihiro Murano; Akira Igarashi; Keiko Yamauchi; Sumito Inoue; Masafumi Watanabe
Journal:  EXCLI J       Date:  2019-10-07       Impact factor: 4.068

Review 5.  Targeting EGFR Exon 20 Insertions in Non-Small Cell Lung Cancer: Recent Advances and Clinical Updates.

Authors:  Catherine B Meador; Lecia V Sequist; Zofia Piotrowska
Journal:  Cancer Discov       Date:  2021-07-23       Impact factor: 39.397

6.  Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878).

Authors:  Jonathan W Riess; Karen L Reckamp; Paul Frankel; Jeffrey Longmate; Karen A Kelly; David R Gandara; Caroline M Weipert; Victoria M Raymond; Harold N Keer; Philip C Mack; Edward M Newman; Primo N Lara
Journal:  Clin Lung Cancer       Date:  2021-05-15       Impact factor: 4.840

7.  Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors.

Authors:  YanRu Qin; Hong Jian; Xiaoling Tong; Xue Wu; Fufeng Wang; Yang W Shao; Xinmin Zhao
Journal:  Mol Oncol       Date:  2020-06-15       Impact factor: 6.603

Review 8.  Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience.

Authors:  Biagio Ricciuti; Sara Baglivo; Andrea De Giglio; Rita Chiari
Journal:  Ther Adv Respir Dis       Date:  2018 Jan-Dec       Impact factor: 4.031

9.  Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma.

Authors:  Seok-Young Kim; Ji Yeon Lee; Dong Hwi Kim; Hyeong -Seok Joo; Mi Ran Yun; Dongmin Jung; Jiyeon Yun; Seong Gu Heo; Beung -Chul Ahn; Chae Won Park; Kyoung Ho Pyo; You Jin Chun; Min Hee Hong; Hye Ryun Kim; Byoung Chul Cho
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379

10.  Poor effect of osimertinib on EGFR exon 20 insertion-positive lung adenocarcinoma: A case report.

Authors:  Yuji Inagaki; Akihiro Tamiya; Yoshinobu Matsuda; Kouji Azuma; Yuichi Adachi; Takatoshi Enomoto; Shunichi Kouno; Yoshihiko Taniguchi; Nobuhiko Saijo; Kyoichi Okishio; Shinji Atagi
Journal:  Medicine (Baltimore)       Date:  2020-10-16       Impact factor: 1.817
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.